Idioma:

Treatment of Graves' disease in Brazil: results of a survey among endocrinologists

Villagelin, Danilo ; Mazeto, Glaucia M F S ; Mesa, Junior, Cléo Otaviano ; Ramos, Helton Estrela ; Scheffel, Rafael Selbach ; Chiamolera, Maria Izabel ; Perini, Nicolas ; Ronconi, Thiago Luis ; Texeira, Patricia

Archives of Endocrinology and Metabolism, 2023-06, Vol.67 (6), p.e000657

Brazil: Brazilian Society of Endocrinology and Metabolism

Texto completo disponível

Citações Citado por

Enviar para

Título:
Treatment of Graves' disease in Brazil: results of a survey among endocrinologists
Autor: Villagelin, Danilo ; Mazeto, Glaucia M F S ; Mesa, Junior, Cléo Otaviano ; Ramos, Helton Estrela ; Scheffel, Rafael Selbach ; Chiamolera, Maria Izabel ; Perini, Nicolas ; Ronconi, Thiago Luis ; Texeira, Patricia
Assuntos: Antithyroid Agents - adverse effects ; Brazil ; Endocrinologists ; Female ; Graves Disease - drug therapy ; Graves Ophthalmopathy - drug therapy ; Graves' disease ; Humans ; hyperthyroidism treatment ; Pregnancy ; Surveys and Questionnaires ; Treatment
É parte de: Archives of Endocrinology and Metabolism, 2023-06, Vol.67 (6), p.e000657
Descrição: The objective of the study was to determine how physicians in Brazil manage Graves' disease in different scenarios including extrathyroidal manifestations. This study was conducted via a digital survey. The respondents (n = 573) answered multiple-choice questions based on a clinical case and variations of the case regarding laboratory and imaging evaluation, treatment choice, and follow-up. The preferred initial treatment chosen by 95% of the respondents was ATD with a preferred treatment duration of 18-24 months. For 5% of the respondents, RAI was the initial treatment of choice. None of the respondents chose thyroidectomy. When presented with a patient with a desire for pregnancy in the near future, most respondents (69%) opted for ATD as the initial treatment. For a patient with signs of mild to moderate Graves' orbitopathy, ATD remained the initial therapy for 93.9% of the respondents. For patients initially treated with ATD with disease recurrence after ATD interruption, most respondents (60%) chose definitive treatment with RAI. A similar survey published in 2011 by Burch and cols. had results comparable to those of the present survey but with a higher proportion of respondents choosing RAI (45% in the 2011 survey versus 5% in the present survey). Brazilian endocrinologists choose ATD as the initial management of Graves' disease, and most choose RAI as a definitive treatment for a patient with relapse after ATD therapy.
Editor: Brazil: Brazilian Society of Endocrinology and Metabolism
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Anterior Resultado 10 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Treatment of Graves' disease in Brazil: results of a survey among endocrinologists

Villagelin, Danilo ; Mazeto, Glaucia M F S ; Mesa, Junior, Cléo Otaviano ; Ramos, Helton Estrela ; Scheffel, Rafael Selbach ; Chiamolera, Maria Izabel ; Perini, Nicolas ; Ronconi, Thiago Luis ; Texeira, Patricia

Brazil: Brazilian Society of Endocrinology and Metabolism

Buscando em bases de dados remotas. Favor aguardar.